PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

The U.S. Food and Drug Administration on Friday approved a new ​formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ‌scanning access through increased production ...

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

Abstract: Storage of a compressed deterministic scan-based test set in an on-chip memory allows compact test sets with complete fault coverage of target faults to be applied in-field. With in-field ...

Rachel works as a CRNA where she provides anesthesia care across the lifespan, including pediatric anesthesia, with a primary focus on orthopedic anesthesia. She is also an Assistant Professor at the ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

New Delhi: In a shocking incident, a six-year-old boy died during an MRI scan at a private diagnostic centre in Greater Noida. The child’s family has accused the diagnostic centre of medical ...

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

You have access Socio-Economic/Ethnicity Characteristics Associated with PET vs. Bone Scan Utilization at a Quaternary-Care Academic Hospital in the PSMA Era: a Preliminary Analysis Lily Offit, Ukasha ...

A negative PSMA-PET/CT at BCR identified a favorable-risk group with 2- and 5-year PFS of 78.3% and 62.4%, respectively, despite no visible lesions. Whole-pelvis radiotherapy improved PFS in locally ...